Streetwise Live! – Algernon Pharmaceuticals CEO Christopher Moreau and Dr. David Nutt Discuss Phase 1 DMT Study For Stroke
Algernon Pharmaceuticals Inc. CEO Christopher J. Moreau and …
Proactive Investors Interview – Algernon Pharmaceuticals Phase 2 Human Study of Ifenprodil for IPF and Chronic Cough is Now 70% Enrolled
Algernon Pharmaceuticals (CSE: AGN – OTCQB: AGNPF) CEO …
Stockhouse – Algernon Pharmaceuticals Makes Major Headway Toward Clinical Trials for Treatment of Stroke
Finding an effective method of preventing the possibility of stroke …